Ocuphire Pharma, Inc.
OCUPDrugs in Pipeline
9
Phase 3 Programs
5
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist
Mesopic Vision
Phentolamine Opthalmic Solution 0.75%
Presbyopia
0.75% phentolamine ophthalmic solution
Presbyopia
Phentolamine Ophthalmic Solution Vehicle
Mydriasis
Phentolamine Ophthalmic Solution 0.75%
Mydriasis
Phentolamine Mesylate Ophthalmic Solution 1%
Open Angle Glaucoma
Pilocarpine
Presbyopia
APX3330
Diabetic Retinopathy
Phentolamine Mesylate Ophthalmic Solution 1.0%
Night Vision Complaints
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist | Phase 3 | Mesopic Vision | - | - |
Phentolamine Opthalmic Solution 0.75% | Phase 3 | Presbyopia | - | - |
0.75% phentolamine ophthalmic solution | Phase 3 | Presbyopia | - | - |
Phentolamine Ophthalmic Solution Vehicle | Phase 3 | Mydriasis | - | - |
Phentolamine Ophthalmic Solution 0.75% | Phase 3 | Mydriasis | - | - |
Phentolamine Mesylate Ophthalmic Solution 1% | Phase 2 | Open Angle Glaucoma | - | - |
Pilocarpine | Phase 2 | Presbyopia | - | - |
APX3330 | Phase 2 | Diabetic Retinopathy | - | - |
Phentolamine Mesylate Ophthalmic Solution 1.0% | Phase 2 | Night Vision Complaints | - | - |